Abstract
Evidence about the treatment of hospitalized type 2 diabetes patients with incretin-based therapy has emerged in the past 15 years. Based on this evidence, dipeptidyl peptidase-4 inhibitors should be considered for hospitalized patients with type 2 diabetes and an algorithm for this is proposed. In relation to use of glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonist, further research is required to help define their role in the inpatient setting.